HC Wainwright & Co. Initiates Coverage On Palisade Bio with Buy Rating, Announces Price Target of $7

HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Palisade Bio (NASDAQ:PALI) with a Buy rating and announces Price Target of $7.